skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hello Peter & Team,

Everyone is starting to focus on how to re-open the economy and what it might look like. All Elective Surgeries were cancelled as well all know, and as a result there is an estimated 30,000 patients who have had their surgery put on hold. Catching up on the back-log is going to take a number of years.

The private sector is going to be heavily leaned to help with this catch-up. Do you have any idea which companies and/or sector(s) might benefit from this in the coming years?

Thanks for all you do

gm
Read Answer Asked by Gord on May 11, 2020
Q: Hi Guys
Thanks for all your help during this little blip in the market. Thinking that with the new focus on Covid-19 treatment, medical supply companies might be a good investment, at least in terms of consumables. Do you think that might be a wise investment and if so do you have any favourites at this time?

Thanks

Stuart
Read Answer Asked by Stuart on March 17, 2020
Q: Good afternoon,
Looking to add US healthcare to my portfolio. I would appreciate your thoughts and ranking on the following US healthcare and service providers; MCK, BDX, SYK, UNH, HUM and MDT. I am open to other recommendations.
Thank you,
Patrick
Read Answer Asked by Patrick on December 09, 2019
Q: I have held MO for over 10 years. It's done very well for me - tripled in value plus dividends. But it's probably time to move on. Traditional tobacco product sales are declining rapidly (not a bad thing to be honest) and investments in JUUL and Cannibis are probably years away from potentially paying off. I'm comfortable with my portfolio make up except for healthcare, which i have no exposure to. I've been looking at ISRG, TMO, BSX and BDK. I'm leaning towards ISRG based on their balance sheet (lots of cash, very little debt),market position, and potential growth but it seems to be in the doghouse after an earnings miss last quarter and it looks expensive on a fwd P/E basis. That said I don't mind paying up for quality. Your thoughts on ISRG or maybe one of the other stocks I listed? Deduct as many credits as you see fit. Thanks in advance.
Read Answer Asked by Richard on June 03, 2019
Q: Hi Team, sold my shares of RHT this morning. Transferring remaining capital from sale to US RRSP for another healthcare name. Someone on T.V last night was screaming Medtronic for a buy ,from my own readings and research I see Stryker as a good choice. Between the 2 which has a better growth profile. Which would you choose. I own ABBV and BDX for a total healthcare exposure of 17%. I Thank-you in advance! Like usual,......Great work team! Sam
Read Answer Asked by sam on October 17, 2018
Q: I recently took over a portfolio of mine managed by a regular at BNN with so so results. Five of the worst performers I would like to know if any of them have a chance of recovery within the next year,
BDX - Cost 280.1
FDX - Cost 274.9
FRU - Cost 15.00
ORCL - Cost 62.3
XLP - Cost 72.6
Thanks for making me confident to take over something like this on my own. Dennis
Read Answer Asked by Dennis on August 07, 2018
Q: In my research of BDX the forward PE ratio is 19.7 or 6% higher than its 5yr avg, but when I look at the PEG it is 1.4 or 23% lower than its 5yr average. What measure is more appropriate to gauge its relative valuation?
Secondly, how much weight do you put into the ROE when looking at a company, the ROE for BDX is only 0.3%, is this alone a reason to stay away from this company?
What grade would you give this company?

Thanks
Read Answer Asked by Albert on June 26, 2018
Q: Could you please rank these USA healthcare stocks in terms of long term capital appreciation. No immediate need for income, looking more for growth. Besides these names, do you see any other interesting healthcare names in the USA with good long term growth prospects? Thanks as always
Read Answer Asked by Aaron on March 21, 2018
Q: The above group of companies, so called bond proxies medical supply and consumer staples do not seem to be participating in the Trump boost post election. Many have sold off sharply. Do you view this as a buying opportunity?
Read Answer Asked by Andrew on November 29, 2016